COVID-19 Vaccine Eligibility
Vaccination is one of the most important tools to end the COVID-19 pandemic.
You are eligible to receive a COVID-19 vaccination if you are 5 years of age and older for Pfizer-BioNTech and 18 years of age and older for Moderna and Janssen/Johnson & Johnson.
The County of San Diego supports a COVID-19 booster for anyone 18 and older who wants one and who meets the California Department of Public Health (CDPH) guidelines for time between doses.
For more information on California's vaccination plan, click here.
COVID-19 Vaccines, Additional Dose, and Booster
|Vaccine Brand||Dose & Recommended Timeline||Timeline||
|Pfizer-BioNTech (Comirnaty)|| |
|at least 21 days after the 1st dose|| |
||✓ ||✓ |
|at least 28 days after 2nd Pfizer dose||✘||✓||✓||✓||✓|
|at least 6 months after 2nd Pfizer dose||✘||✘||✓||✓||✓|
Booster (4th) dose**
|at least 6 months after 3rd Pfizer dose||✘||✘||✓||✓||✓|
|at least 28 days after the 1st dose||✘||✘||✓||✓||✓|
|at least 28 days after 2nd Moderna dose||✘||✘||✓||✓||✓|
|at least 6 months after 2nd Moderna dose||✘||✘||✓||✓||✓|
Booster (4th) dose**
|at least 6 months after 3rd Moderna dose||✘||✘|| |
|Janssen/Johnson & Johnson||1 dose||✘||✘||✓||✓||✓|
|at least 2 months after primary Janssen/Johnson & Johnson dose||✘||✘||✓||✓||✓|
|Table updated on November 16, 2021|
*An additional dose is recommended by the Centers for Disease Control and Prevention (CDC) for moderately to severely immunocompromised people four weeks after receiving the second Pfizer-BioNTech or Moderna vaccine. An additional dose is needed because immunocompromised people sometimes do not build enough protection after the first two doses. Only ages 12 through 17 years old who received the Pfizer COVID-19 vaccine are eligible for an additional dose.
**A booster dose is recommended for people 18 years or older and has met the 6-month original vaccination series time period for the Pfizer or Moderna vaccine or it has been at least 2 months since their J&J vaccine. Individuals may self-determine their risk of exposure. The person’s assessment of risk exposure may include, but is not limited to, those who work with the public or live with someone who works with the public, live or work with someone at high risk of severe impact of COVID, live in geographic areas that have been heavily impacted by COVID-19, reside in high transmission areas, live in a congregate setting, experience social inequity, or other risk conditions as assessed by the individual.
Additional and Booster Doses
A booster dose is not to be confused with those who qualify for an additional dose, recommended for moderately to severely immunocompromised people who may not build enough protection after the first two doses. When you go to receive your booster dose, please bring your vaccination card.
As of November 9, 2021, CDPH recommends the following groups of people who received the Pfizer, Moderna, or J&J COVID-19 vaccines should receive a booster dose using any one of the three approved or emergency use authorized (EUA) COVID-19 vaccines:
- Ages 18 years and older who have met the 6-month original vaccination series time period for the Pfizer or Moderna vaccine or it has been at least 2 months since their J&J vaccine.
Individuals may choose which of the three vaccines they would like to receive if they are eligible for a booster dose. The CDC have expanded the recommendations for booster doses to allow heterologous (mix and match) dosing.
A booster dose is recommended for people 18 years or older and has met the 6-month original vaccination series time period for the Pfizer or Moderna vaccine or it has been at least 2 months since their J&J vaccine. Since one’s immunity to COVID-19 may wane over time, a booster dose is needed to maintain longer protection.
Booster Doses for WHO-Listed COVID-19 Vaccines Not Approved in the United States
People who received a WHO-listed COVID-19 vaccine not approved by the FDA are eligible to receive a single booster dose of Pfizer-BioNTech COVID-19 vaccine if they fall into one of the groups at increased risk for serious complications of COVID-19 or exposure to SARs-CoV-2 as detailed in Considerations for Use of COVID-19 Vaccines.
For Pfizer-BioNTech and Moderna COVID-19 vaccines, CDC recommends receiving the second dose of the series within 6 weeks (42 days) after the first dose. If you cannot get vaccinated within that exact timeframe, you do not need to restart the series.
- The U.S. Food and Drug Administration (FDA) and CDC have recommended use of the Janssen/Johnson & Johnson (J&J) COVID-19 vaccine resume in the United States, after a temporary pause on 04/13/2021. Individuals getting the J&J COVID-19 vaccine will be asked to review the latest guidance prior to being vaccinated.
- View Fact Sheet: Johnson & Johnson COVID-19 Vaccine Benefits and Risks (CDPH) - English
- View Fact Sheet: Johnson & Johnson COVID-19 Vaccine Benefits and Risks (CDPH) - Spanish
COVID-19 Vaccination Phases
✓ Phase 1A - as of December 14, 2020
- Staff working in acute care, psychiatric, and correctional facility hospitals1
- Staff working in skilled
nursing facilities, assisted living facilities, and similar
- Includes residents in these long-term care settings
- Paramedics, EMTs, and other staff providing emergency medical services
- Staff working in
- Staff working in behavioral health
- Includes residents in these behavioral health residential facilities
- Staff providing intermediate care, for persons who need non-continuous nursing supervision, and supportive care
- Staff providing in home health-care and in-home supportive services
- Community health workers, including promotores
- Public Health field staff
- Staff working in primary care clinics
- Staff working in Federally Qualified Health Centers
- Staff working in Rural Health Centers
- Staff working in correctional facility clinics
- Staff working in urgent care clinics
- Staff working in
behavioral health non-residential or outpatient facilities
- Includes residents in these behavioral health non-residential or outpatient facilities
- Other settings and healthcare personnel, including:
- Specialty clinics, laboratory workers2, dental/oral health clinics, pharmacy staff, and funeral workers, massage therapists, and others.
- Couriers for vaccines and emergency supplies.
✓ Phase 1B
- Persons aged 75 years and older - as of January 18, 2021
- Persons 65-74 years of age - as of January 23, 2021
- Persons at risk of occupational exposure through
their work in the following sectors - as of February 27,
- Emergency Services (includes emergency operations and disaster service workers, fire, law enforcement, social workers, and utility workers)
- Childcare and Education
- Food and Agriculture
Additional Groups - as of February 27, 2021
✓ Phase 1C - as of March 15, 2021
High-Risk Medical Conditions and Disabilities
People ages 16-64 deemed to be at the very highest risk to get very sick from COVID-19
EITHER because they have one or more of the following health conditions:
- Cancer, current with weakened immune system
- Chronic kidney disease, stage 4 or above
- Chronic pulmonary disease, oxygen dependent
- Down syndrome
- Solid organ transplant, leading to a weakened immune system
- Sickle cell disease
- Heart conditions, such as heart failure, coronary artery disease, or cardiomyopathies (but not hypertension)
- Severe obesity (Body Mass Index ≥ 40 kg/m2)
- Type 2 diabetes mellitus with hemoglobin A1c level greater than 7.5%
OR if, as a result of a developmental or other significant, high-risk disability, one or more of the following criteria applies**:
- A COVID-19 infection is likely to result in severe life-threatening illness or death; OR
- Acquiring COVID-19 will limit the individual’s ability to receive ongoing care or services vital to their well-being and survival; OR
- Providing adequate and timely COVID care will be particularly challenging as a result of the individual’s disability.
Additional Medical Conditions
Based on what we know at this time, those with the following conditions might be at an increased risk of severe illness from the virus that causes COVID-19; therefore they are also eligible for COVID-19 vaccine:
- Asthma (moderate-to-severe)
- Cerebrovascular disease (affects blood vessels and blood supply to the brain)
- Cystic fibrosis
- Hypertension or high blood pressure
- Immunocompromised state (weakened immune system) from blood or bone marrow transplant, immune deficiencies, HIV, use of corticosteroids, or use of other immune weakening medicines
- Neurologic conditions, such as dementia
- Liver disease
- Overweight (BMI > 25 kg/m2, but < 30 kg/m2)
- Obese (BMI > 30 kg/m2, but < 40 kg/m2)
- Pulmonary fibrosis (having damaged or scarred lung tissues)
- Thalassemia (a type of blood disorder)
- Type 1 diabetes mellitus
- Congregate residential settings, such as an
incarceration/detention facilities, homeless shelters, or
behavioral health facilities
- Includes people experiencing homelessness, who may transition into congregate settings at short notice
- Public transit workers, including airport workers for commercial airlines (but not private airplanes)
- General population 50 years of age and older - as of April 1, 2021
- General population 16 years of age and older - as of April 15, 2021
- U.S. citizens living in Baja California - as of May 6, 2021
- General population 12 years of age and older - as of May 13, 2021
Distribution was based upon phases determined by Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) and tiers approved by CDPH. Subject to change pending vaccine supply and local recommendations.
**Examples include: all enrolled consumers of Regional Centers, Independent Living Centers, In Home Supportive Services, Community Based Adult Services/Adult Day Health Centers, Medi-Cal HIV/AIDS Waiver, Medi-Cal Home and Community-Based Alternatives Waiver, Medi-Cal Assisted Living Waiver, Program of All-Inclusive Care for the Elderly, California Children’s Services Program (if the child is 16-21 years old), and California Genetically Handicapped Persons Program.
1No correctional facility hospitals exist within San Diego
2Laboratory workers must either work in a CLIA licensed laboratory or be conducting research with SARS-CoV-2.